06855 ASCENTAGE-B
- 20.550
- -0.250-1.20%
ASCENTAGE-B News
Express News | CITIC Construction Investment: The national biotechnology and biomanfacture action plan is expected to be introduced in the near future, and the subsequent implementation of the policy is worth looking forward to
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Ascentage Pharma to Present Four Studies at US Oncology Meet
Ascentage Pharma Group International (HKG:6855) will present data from four studies at an oncology meeting in the US from May 31 to June 4, according to a Thursday filing with the Hong Kong bourse. Th
Yasheng Pharmaceutical-B (06855): Four studies were selected for the ASCO Annual Meeting, and the latest progress of Nellick's treatment of SDH-deficient GIST was presented orally
Zhitong Finance App News, Yasheng Pharmaceutical-B (06855) issued an announcement. Four clinical studies of the company's three key varieties were selected for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, and one of them received an oral report. These three key varieties are the first and only third-generation BCR-ABL inhibitor approved for marketing in China, olebatinib (HQP1351; trade name: Nelick), the Bcl-2 selective inhibitor APG-2575, and the FAK/ALK/ROS1 triple inhibitor APG-2449. The annual ASCO annual conference is the field of global oncology
亞盛醫藥-B：2023年報
Ascentage Pharma Chairman Boosts Stake in Firm
Ascentage Pharma Group International (HKG:6855) Chairman Yang Dajun acquired an additional 80,000 ordinary shares in the company for approximately HK$1.4 million or HK$17.08 apiece. According to the f
Some Hong Kong biotech stocks rose higher, and Cansino Biotech rose more than 10%
Glonghui, April 9 | Cansino Biotech rose more than 10%, Yiming Anke rose more than 9%, and Yasheng Pharmaceutical rose more than 6%.
Yasheng Pharmaceutical-B (06855.HK) was increased by 80,000 shares of the company by Executive Director and Chairman Yang Dajun
Yasheng Pharmaceutical-B (06855.HK) announced that the company was informed by Yang Dajun, the company's executive director and chairman of the board of directors, that on April 5, 2024 and April 8, 2024, he subscribed for a total of 80,000 shares of the company's common shares. The total cost was about HK$1,3662 million. The average price was about HK$17.08 per share, accounting for about 0.028% of the company's total issued share capital on the date of this announcement.
Yasheng Pharmaceutical-B (06855.HK) three research advances unveiled at the 2024 American Association for Cancer Research Annual Meeting
Yasheng Pharmaceutical-B (06855.HK) announced three preclinical research results at the 2024 American Association for Cancer Research (AACR) annual meeting, involving the company's original Class 1 drug olevatinib (trade name: Nelick), MDM2-p53 inhibitor APG-115, FAK/ALK/ROS1 triple tyrosine kinase inhibitor APG-2449, and the embryonic ectodermal development protein (EED) inhibitor APG-5918.
Ascentage Pharma Group Directors Acquire Company Shares
Ascentage Pharma Group International (HKG:6855) said Wang Shaomeng, a non-executive director, and Yang Dajun, an executive director, acquired shares of the company on-market, according to a Wednesday
Ascentage Pharma Widens Loss by Nearly 5% in 2023
Ascentage Pharma (HKG:6855) recorded a 4.8% rise in attributable loss for the year ended Dec. 31, 2023, to 925.6 million yuan from 882.9 million yuan during the year-ago period, a Wednesday filing on
Focusing on building a closed loop of global R&D, production and marketing innovation, Yasheng Pharmaceutical-B (06855) is steadily transforming and developing into Biopharma
Relying on systematic advantages formed in various aspects such as global R&D, overseas registration, and market commercialization, Yasheng Pharmaceutical continues to realize its hematopoietic potential while also pushing innovative research and development to a new level, further improving its “positive cycle” of transition to Biopharma.
Yasheng Pharmaceutical (6855.HK): Multiple Indications Continue to Accelerate Overseas Progress
Event: The company released its 2023 annual report and achieved revenue of 220 million yuan in 2023. The revenue mainly comes from product sales and cooperation milestone revenue, of which the company's product sales revenue was RMB 194 million. Is olevatinib new
Yasheng Pharmaceutical (6855.HK) Announces 2023 Results: Continued Improvement of Self-hematopoietic Capability, Rich Product Pipeline Potential
Gelonghui, March 27 | Yasheng Pharmaceutical (6855.HK) announced its 2023 results: achieved revenue of RMB 222 million, mainly from product sales and cooperation milestone revenue. Nellick, the marketed product of Yasheng Pharmaceutical, is currently the first and only third-generation BCR-ABL inhibitor approved for marketing in China. In January 2023, Nellick was included in the 2022 National Medical Insurance Drug List as a “benchmark for domestically produced innovative drugs”, greatly improving the accessibility of medication for patients and accelerating the commercialization of this product. On November 17, Nellick's new indications were approved to be marketed for the treatment of the first generation and the second generation
Yasheng Pharmaceutical-B (06855) Announces 2023 Results Global Clinical Development Ends Harvest Period
Zhitong Finance App News, on March 27, Yasheng Pharmaceutical-B (06855) announced its 2023 annual results: Yasheng Pharmaceuticals achieved total revenue of RMB 222 million during the reporting period. As Nellick, the core product of Yasheng Pharmaceutical, is included in the national medical insurance catalogue and approved for marketing for new indications, as well as by speeding up admission, patient accumulation, and extending the duration of medication, it is expected that more patients will benefit from Nellick's treatment plan, driving sales growth in 2024. Financial reports show that while the commercial self-hematopoietic capacity continues to improve, Yasheng Pharmaceutical is rapidly advancing the patient-centered “global innovation” strategy.
ASCENTAGE-B: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2023
Yasheng Pharmaceutical-B (06855.HK) will hold a board meeting on March 27 to approve the annual results
Gelonghui, March 15, 丨 Yasheng Pharmaceutical-B (06855.HK) announced that the company will hold a board meeting on March 27, 2024 to consider and approve the Group's annual results for the year ended December 31, 2023, and consider paying a final dividend (if any).
ASCENTAGE-B: NOTICE OF BOARD MEETING
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Analysis
Price Target
No Data
